Haleon plc (HLN)vsLiquidia Technologies Inc (LQDA)
HLN
Haleon plc
$9.25
-1.18%
HEALTHCARE · Cap: $40.48B
LQDA
Liquidia Technologies Inc
$68.64
+3.33%
HEALTHCARE · Cap: $5.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 2373% more annual revenue ($11.15B vs $450.91M). LQDA leads profitability with a 30.7% profit margin vs 14.5%. HLN trades at a lower P/E of 18.8x. LQDA earns a higher WallStSmart Score of 60/100 (C).
HLN
Buy51
out of 100
Grade: C-
LQDA
Buy60
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 23.9%
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 49.8%
Revenue surging 1843.0% year-over-year
Every $100 of equity generates 28 in profit
Areas to Watch
Expensive relative to growth rate
2.2% revenue growth
Grey zone — moderate risk
Earnings declined 4.5%
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 31.3x book value
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : HLN
The strongest argument for HLN centers on Price/Book, Operating Margin.
Bull Case : LQDA
The strongest argument for LQDA centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 30.7% and operating margin at 49.8%. Revenue growth of 1843.0% demonstrates continued momentum.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth, Altman Z-Score.
Bear Case : LQDA
The primary concerns for LQDA are EPS Growth, P/E Ratio, Price/Book. A P/E of 47.5x leaves little room for execution misses.
Key Dynamics to Monitor
HLN profiles as a value stock while LQDA is a growth play — different risk/reward profiles.
LQDA carries more volatility with a beta of 0.54 — expect wider price swings.
LQDA is growing revenue faster at 1843.0% — sustainability is the question.
HLN generates stronger free cash flow (792M), providing more financial flexibility.
Bottom Line
LQDA scores higher overall (60/100 vs 51/100), backed by strong 30.7% margins and 1843.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company, emerging as a spin-off from GlaxoSmithKline, dedicated to providing innovative health solutions through a robust portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. Focused on key segments such as oral care, pain relief, and dietary supplements, Haleon addresses evolving consumer needs while leveraging strong brand equity for sustained market presence. The company's commitment to sustainability and ongoing innovation, alongside strategic investments in product development, positions Haleon favorably for long-term growth and enhanced health outcomes, ultimately maximizing value for shareholders.
Visit Website →Liquidia Technologies Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and markets various products for the unmet needs of patients in the United States. The company is headquartered in Morrisville, North Carolina.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?